Kirsten M Williams, Steven Z Pavletic, Stephanie J Lee, Paul J Martin, Don E Farthing, Frances T Hakim, Jeremy Rose, Beryl L Manning-Geist, Juan C Gea-Banacloche, Leora E Comis, Edward W Cowen, David G Justus, Kristin Baird, Guang-Shing Cheng, Daniele Avila, Seth M Steinberg, Sandra A Mitchell, Ronald E Gress
Bronchiolitis obliterans syndrome (BOS) is a severe manifestation of chronic graft-versus-host disease (cGVHD) following hematopoietic cell transplantation (HCT). Montelukast interrupts cysteinyl leukotriene (CysLT) activity and may diminish the activation and homing of cells to bronchioles and subsequent fibrosis. We performed a prospective phase II trial to test whether montelukast altered lung decline for patients with BOS after HCT. In this single-arm, open-label, multi-institutional study, the primary endpoints were stability or improvement (<15% decline) in forced expiratory volume in 1 second (FEV1) and a <1-point decline in the slope of FEV1 after 6 months of treatment...
February 1, 2022: Transplantation and cellular therapy